Esperion Therapeutics Inc (ESPR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Esperion Therapeutics Inc (ESPR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8031
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Esperion Therapeutics Inc (Esperion), a subsidiary of Pfizer Inc is a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol lowering therapies. The company develops oral therapies to treat patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate, Bempedoic acid is an ATP-citrate lyase inhibitor which is in Phase 3 clinical development that reduces elevated LDL-C levels in patients with hypercholesterolemia. The company also offers development of bempedoic acid in a fixed dose combination with ezetimibe, an LDL-C lowering therapy. Esperion is headquartered in Ann Arbor, Michigan, the US.

Esperion Therapeutics Inc (ESPR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Esperion Therapeutics Raises US$33 Million In Venture Financing 11
Esperion Therapeutics Raises US$1 Million In Venture Financing 13
Equity Offering 14
Esperion Therapeutics Prices Public Offering of Shares for USD152 Million 14
Esperion Therapeutics Raises USD201 Million in Public Offering of Shares 16
Esperion Therapeutics Raises USD98 Million in Public Offering of Shares 18
Esperion Therapeutics Completes Underwriters’ Exercise Of Over-Allotment Option For IPO For US$70 Million 20
Esperion Therapeutics Inc – Key Competitors 22
Esperion Therapeutics Inc – Key Employees 23
Esperion Therapeutics Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 02, 2018: Esperion provides Bempedoic Acid franchise development program updates; reports second quarter 2018 financial results 25
May 02, 2018: Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results 28
Feb 20, 2018: Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results 29
Nov 07, 2017: Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results 31
Aug 08, 2017: Esperion Reports Second Quarter 2017 Financial Results 33
May 04, 2017: Esperion Reports First Quarter 2017 Financial Results 34
May 04, 2017: Esperion Therapeutics Q1 net loss up 35
Feb 22, 2017: Esperion Reports Fourth Quarter and Full Year 2016 Financial Results 36
Corporate Communications 37
Aug 11, 2017: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 37
Legal and Regulatory 39
May 10, 2018: Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics 39
May 07, 2018: Pomerantz Law Firm Announces the Filing of a Class Action against Esperion Therapeutics and Certain Officers – ESPR 40
Product Approvals 41
Jun 26, 2017: Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe 41
Clinical Trials 42
Nov 06, 2017: Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill 42
Aug 08, 2017: Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Esperion Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Esperion Therapeutics Raises US$33 Million In Venture Financing 11
Esperion Therapeutics Raises US$1 Million In Venture Financing 13
Esperion Therapeutics Prices Public Offering of Shares for USD152 Million 14
Esperion Therapeutics Raises USD201 Million in Public Offering of Shares 16
Esperion Therapeutics Raises USD98 Million in Public Offering of Shares 18
Esperion Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$70 Million 20
Esperion Therapeutics Inc, Key Competitors 22
Esperion Therapeutics Inc, Key Employees 23

List of Figures
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Esperion Therapeutics Inc (ESPR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cinnabon LLC:企業の戦略・SWOT・財務情報
    Cinnabon LLC - Strategy, SWOT and Corporate Finance Report Summary Cinnabon LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Prestige Brands Holdings Inc (PBH):製薬・医療:M&Aディール及び事業提携情報
    Summary Prestige Brands Holdings Inc (Prestige) focuses on the marketing, sales and distribution of over-the-counter (OTC) healthcare and household cleaning brands. The company offers its products for digestive care; lice treatment, household cleaning; hygiene; oral care; pain relief; pediatric care …
  • NextEra Energy Inc (NEE):企業の財務・戦略的SWOT分析
    NextEra Energy Inc (NEE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Page Industries Ltd:企業の戦略・SWOT・財務分析
    Page Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Page Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Mitsubishi Motors Corporation (7211):企業の財務・戦略的SWOT分析
    Mitsubishi Motors Corporation (7211) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • International Consolidated Airlines Group, S.A.:企業の戦略・SWOT・財務分析
    International Consolidated Airlines Group, S.A. - Strategy, SWOT and Corporate Finance Report Summary International Consolidated Airlines Group, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Petsec Energy Ltd (PSA):石油・ガス:M&Aディール及び事業提携情報
    Summary Petsec Energy Ltd (Petsec Energy) is an oil and gas company that offers oil and gas exploration, development, and production. The Company holds interests in two oil and gas production fields located onshore Louisiana, the US in Mystic Bayou and Jeanerette Fields. It provides leases, explorat …
  • Protagen AG:医療機器:M&Aディール及び事業提携情報
    Summary Protagen AG (Protagen) is a medical device company that develops molecular diagnostic and companion diagnostic test equipment. The company’s products include multilisa SSC, multilisa SLE and multilisa RA. It provides products for autoimmune diseases such as rheumatoid arthritis, neuromyeliti …
  • Fagron NV (FAGR)-医療機器分野:企業M&A・提携分析
    Summary Fagron NV (Fagron), formerly Arseus NV is a provider of pharmaceutical compounding solutions. The company provides compounding essentials, trademarks, and pharma services to pharmacies, hospitals and clinics. Its compounding services provide customized pharmaceutical products for specific pa …
  • Altimmune Inc (ALT):製薬・医療:M&Aディール及び事業提携情報
    Summary Altimmune Inc (Altimmune), formerly Vaxin Inc is an immunotherapeutics company that develops vaccines and other biological products. The company’s products include nasovax, an intranasally administered recombinant influenza vaccine; and heptcell, an immunotherapy for patients chronically inf …
  • State Atomic Energy Corporation Rosatom:企業の戦略的SWOT分析
    State Atomic Energy Corporation Rosatom - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Suncorp Group Ltd:企業の戦略・SWOT・財務情報
    Suncorp Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Suncorp Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Wolters Kluwer nv:企業の戦略・SWOT・財務情報
    Wolters Kluwer nv - Strategy, SWOT and Corporate Finance Report Summary Wolters Kluwer nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Standex International Corp:企業の戦略・SWOT・財務情報
    Standex International Corp - Strategy, SWOT and Corporate Finance Report Summary Standex International Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • International Data Group:戦略・SWOT・企業財務分析
    International Data Group - Strategy, SWOT and Corporate Finance Report Summary International Data Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Sinphar Pharmaceutical Co Ltd (1734):企業の財務・戦略的SWOT分析
    Sinphar Pharmaceutical Co Ltd (1734) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Gjensidige Forsikring ASA :企業のM&A・事業提携・投資動向
    Gjensidige Forsikring ASA  - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gjensidige Forsikring ASA  Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Cryosite Ltd (CTE):企業の財務・戦略的SWOT分析
    Summary Cryosite Ltd (Cryosite) is a healthcare solution provider that offers clinical trials outsourced logistics services to research, medical, pharmaceutical, veterinary and biotechnology industries. The company manufactures stem cell products for both therapeutic use and clinical trials. It prov …
  • WEC Energy Group:企業の戦略・SWOT・財務情報
    WEC Energy Group - Strategy, SWOT and Corporate Finance Report Summary WEC Energy Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • TransAlta Corporation:企業の戦略・SWOT・財務分析
    TransAlta Corporation - Strategy, SWOT and Corporate Finance Report Summary TransAlta Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆